- Home
- TNGX vs CRI Comparison
TNGX vs CRI Comparison
Compare TNGX & CRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- CRI
- Stock Information
- Founded
- TNGX 2014
- CRI 1865
- Country
- TNGX United States
- CRI United States
- Employees
- TNGX N/A
- CRI N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- CRI Apparel
- Sector
- TNGX Health Care
- CRI Consumer Discretionary
- Exchange
- TNGX Nasdaq
- CRI Nasdaq
- Market Cap
- TNGX 1.0B
- CRI 1.0B
- IPO Year
- TNGX N/A
- CRI 2003
- Fundamental
- Price
- TNGX $7.99
- CRI $31.69
- Analyst Decision
- TNGX Strong Buy
- CRI Sell
- Analyst Count
- TNGX 6
- CRI 4
- Target Price
- TNGX $10.80
- CRI $29.50
- AVG Volume (30 Days)
- TNGX 4.3M
- CRI 1.3M
- Earning Date
- TNGX 11-04-2025
- CRI 10-27-2025
- Dividend Yield
- TNGX N/A
- CRI 3.15%
- EPS Growth
- TNGX N/A
- CRI N/A
- EPS
- TNGX N/A
- CRI 2.45
- Revenue
- TNGX $66,501,000.00
- CRI $2,832,687,000.00
- Revenue This Year
- TNGX $20.41
- CRI $1.58
- Revenue Next Year
- TNGX N/A
- CRI N/A
- P/E Ratio
- TNGX N/A
- CRI $12.93
- Revenue Growth
- TNGX 53.29
- CRI N/A
- 52 Week Low
- TNGX $1.03
- CRI $23.38
- 52 Week High
- TNGX $9.70
- CRI $58.13
- Technical
- Relative Strength Index (RSI)
- TNGX 49.39
- CRI 54.32
- Support Level
- TNGX $7.12
- CRI $29.40
- Resistance Level
- TNGX $8.17
- CRI $32.66
- Average True Range (ATR)
- TNGX 0.74
- CRI 1.99
- MACD
- TNGX -0.07
- CRI -0.07
- Stochastic Oscillator
- TNGX 45.74
- CRI 48.75
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About CRI Carter's Inc.
Carter's Inc makes apparel for babies and children under brand names including Carter's and OshKosh B'gosh. It sells its products through a multi-channel business model, which includes retail stores, eCommerce, and wholesale sales channels, as well as retail omnichannel capabilities in the United States and Canada, which enables it to reach a broad range of consumers around the world. The company operates in three segments; U.S. Retail, U.S. Wholesale, and International. The majority of revenue is derived from U.S. Wholesale segment. The company predominantly sources products through contract manufacturers in Asia. It has multiple distribution centers in the U.S., in addition to distribution centers in Canada and Asia that serve international customers.